JHOP - March 2016 Vol 6, No 1

Since the approval of ipilimumab (Yervoy; a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 for late-stage melanoma) in 2011, it may be easier to answer the question: For which types of cancer are immunotherapy agents not effective?
High doses of chemotherapy in patients who undergo autologous hematopoietic stem-cell transplantation (HSCT) can result in delayed or incomplete engraftment. Granulocyte colony-stimulating factors are used to decrease the time to engraftment; however, the optimal timing of filgrastim initiation following autologous HSCT is unknown.
Hypercalcemia is defined as a condition in which the serum calcium level is >10.5 mg/dL (the upper limit of normal) or the ionized calcium level exceeds 5.6 mg/dL. The consequences of abnormally high serum calcium can range from asymptomatic to life-threatening.
Treatment of chronic myeloid leukemia (CML) with imatinib and more recent therapeutic agents has brought a drastic change in the course of this malignancy. Some patients never experience disease progression, and, therefore, may expect long-term survival with such treatment.
  • Aprepitant Effective in Preventing Chemotherapy-Induced Nausea and Vomiting in Children
  • Bevacizumab for Advanced Lung Cancer Does Not Increase Risk for Hospitalization or Unexpected Toxicity
  • Daratumumab, an Anti-CD38 Monoclonal Antibody, Effective Treatment Option for Patients with Relapsed and/or Refractory Multiple Myeloma

Results 1 - 5 of 5